Mumbai, February 23, 2024: Global pharma major Lupin Limited (Lupin)today announced its debut in the esteemed S&P Global Sustainability Yearbook 2024, underscoring its dedication to corporate sustainability. With a notable Corporate Sustainability Assessment (CSA) score of 69/100, Lupin joins the ranks of leading companies recognized for their exemplary environmental, social, and governance (ESG) practices.

The S&P Global Sustainability Yearbook 2024, a benchmark for corporate sustainability performance, evaluated over 9400 companies worldwide, with only 739 earning inclusion. Lupin’s exceptional performance places it within the top 95 percentile for the pharmaceutical sector, showcasing its unwavering commitment to sustainable business practices.

Commenting on this achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – Corporate Affairs, Lupin said, “Lupin’s inclusion in the S&P Global Sustainability Yearbook 2024 underscores our firm commitment to advancing sustainable practices within the pharmaceutical industry. This recognition reaffirms our dedication to creating long-term value for all stakeholders while fostering a healthier, more sustainable future for generations to come.”

Lupin remains steadfast in its mission to prioritize sustainability, drive positive change, and make a meaningful difference in the world.

About S&P Global Sustainability Yearbook 2024
The Sustainability Yearbook aims to distinguish those companies within their industries that have each demonstrated strengths in corporate sustainability. To learn more, please visit:
https://www.spglobal.com/esg/csa/yearbook/methodology/index

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on :
Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: https://www.facebook.com/LupinWorld/

For further information or queries please contact –

Priyanka Chavda
Manager – Corporate Communications
Email: priyankachavda@lupin.com